Upadacitinib

ApprovedRecruiting

0 views this week 0 watching⚡ Active

Interest: 50/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Prurigo Nodularis

Conditions

Prurigo Nodularis

Trial Timeline

Apr 9, 2024 → Jan 1, 2026

NCT ID

NCT06773403

About Upadacitinib

Upadacitinib is a approved stage product being developed by AbbVie for Prurigo Nodularis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06773403. Target conditions include Prurigo Nodularis.

What happened to similar drugs?

0 of 6 similar drugs in Prurigo Nodularis were approved

Approved (0) Terminated (0) Active (6)

🔄Rocatinlimab + PlaceboAmgenPhase 3

🔄DupilumabSanofiPhase 3

🔄Ruxolitinib Cream + Vehicle CreamIncytePhase 3

🔄Povorcitinib + PlaceboIncytePhase 3

🔄Ruxolitinib Cream + Vehicle CreamIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04159597	Pre-clinical	Active	—	—	Crohn Disease
NCT06332534	Phase 3	Recruiting	Jul 26, 2024	Dec 1, 2034	Crohn's Disease
NCT06773403	Approved	Recruiting	Apr 9, 2024	Jan 1, 2026	Prurigo Nodularis
NCT05782907	Phase 3	Active	Nov 6, 2023	Oct 1, 2033	Ulcerative Colitis
NCT05507580	Approved	Completed	May 29, 2023	Aug 15, 2024	Atopic Dermatitis
NCT05094128	Pre-clinical	Recruiting	Nov 22, 2021	Jun 1, 2026	Axial Spondylarthritis (r-axSpA)
NCT04195698	Phase 3	Completed	Jan 15, 2020	Sep 11, 2023	Atopic Dermatitis
NCT03725007	Phase 1	Active	Jun 24, 2019	May 1, 2027	Juvenile Idiopathic Arthritis (JIA)

Competing Products

20 competing products in Prurigo Nodularis

See all competitors

Product	Company	Stage	Hype Score
Vixarelimab + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
Pimecrolimus + Hydrocortisone + Pimecrolimus	Novartis	Phase 2	35
Rocatinlimab + Placebo	Amgen	Phase 3	44
Abrocitinib	Pfizer	Phase 2	35
Dupilumab SAR231893 (REGN668)	Sanofi	Pre-clinical	33
Dupilumab	Sanofi	Phase 3	47
Dupilumab	Sanofi	Pre-clinical	33
Dupilumab	Sanofi	Pre-clinical	30
Ruxolitinib Cream 1.5%	Incyte	Phase 1	26
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	37
INCB054707 + Placebo	Incyte	Phase 2	32
Povorcitinib + Placebo	Incyte	Phase 3	44
Povorcitinib + Placebo	Incyte	Phase 3	44
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	37
CDX-0159 + Normal saline	Celldex Therapeutics	Phase 1	23
barzolvolimab	Celldex Therapeutics	Phase 2	33
nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID	Trevi Therapeutics	Phase 2/3	32
nalbuphine HCl ER	Trevi Therapeutics	Phase 2/3	32
Nalbuphine ER Tablets + Placebo Tablets	Trevi Therapeutics	Phase 2/3	32
serlopitant + Placebo	Vyne Therapeutics	Phase 2	25